Clinical Trials
104 trialsIn Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
Chinese PLA General Hospital
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
National Cancer Institute, Naples
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
CART-BCMA
Chulalongkorn University
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SL4903
Institute of Hematology & Blood Diseases Hospital, China
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
IASO104
Institute of Hematology & Blood Diseases Hospital, China
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Memorial Sloan Kettering Cancer Center
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
CC-220
Icahn School of Medicine at Mount Sinai
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
QLS32015
Institute of Hematology & Blood Diseases Hospital, China
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
University of Rochester
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
CAR19BCMA
Chinese PLA General Hospital
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Peking University First Hospital
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
VitD3 Supplementation in Patients With Multiple Myeloma
Augusta University
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Mayo Clinic
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Tongji Hospital
Study of CT071 Injection in RRMM or PPCL
Shanghai Changzheng Hospital
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Hrain Biotechnology Co., Ltd.
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
64Cu-LLP2A for Imaging Multiple Myeloma
Washington University School of Medicine
CARTinNS
Tongji Hospital
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Shanghai Changzheng Hospital
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Changzhou No.2 People's Hospital